Anti-Tumor Effect of Marshallagia marshalli Somatic Antigen on Inhibition Cell Growth of K562

Raisnia, Reyhane; Mohebalian, Hadi; Sabzevar, Atousa Shahrokhi; Borji, Hassan

doi:10.18502/ijpa.v17i1.9013

Cited by 7 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gravid proglottids release their eggs into the feces, and a suitable intermediate host then ingests them 21,22 . The eggs hatch in the small intestine and release six hooked oncospheres, which can pass through the intestinal wall and migrate through the circulatory system to various organs, especially the liver and lungs 23,24 . A thick‐walled hydatid cyst forms from the Oncosphere's development 25 .…”

Section: Introductionmentioning

confidence: 99%

“…21 , 22 The eggs hatch in the small intestine and release six hooked oncospheres, which can pass through the intestinal wall and migrate through the circulatory system to various organs, especially the liver and lungs. 23 , 24 A thick‐walled hydatid cyst forms from the Oncosphere's development. 25 The progressive growth of hydatid cysts leads to daughter cysts and protoscolices.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of hydatid cyst protoscolex somatic antigens on full‐thickness skin wound healing in mouse

Hosseinzade,

Nourani,

Kazemi Mehrjerdi

et al. 2024

Skin Research and Technology

Self Cite

View full text Add to dashboard Cite

BackgroundWound healing has evolved in recent years, resulting in diverse therapeutic options.ObjectiveThis study evaluated the effects of the somatic antigen of the hydatid cyst protoscolex on wound healing in mice with full‐thickness skin wounds.MethodsFifty‐four adult mice, weighing 25 ± 5 g and approximately 60 days old, were divided into three groups (A, B, and C), each further divided into three subgroups. Subgroups A1, A2, and A3 were assigned negative controls. B1, B2, and B3 received hydatid cyst somatic antigen tests at 10 µg/SC, whereas C1, C2, and C3 received somatic antigen tests at 20 µg/SC. Under general anesthesia, a wound biopsy puncture of 9.8 mm in diameter was performed on the mice's back and spine. In the experimental group, antigen and alum adjuvant were administered subcutaneously around the wound, while the control group received Phosphate‐Buffered Saline (PBS). Using digital images, a geometric assessment was conducted on days 0, 1, 3, 6, 9, 12, 15, 18, and 21 post‐wounding. The obtained images were analyzed by Image J software and after analyzing the data by SPSS software.ResultsA significant difference in terms of epithelization was observed in the antigen treatment group with a dose of 20 µg on days 3 and 6 (P < 0.05). Furthermore, the 20 µg antigen group was significantly higher than the 10 µg antigen group in terms of this factor on day 3 (P < 0.05). Skin samples were taken from all wounds on days 3, 10 and 21 for microscopic evaluation. Regarding epithelization, on day 10, a significant difference was observed in the treatment group with a concentration of 10 µg with the control group and the treatment group with a concentration of 20 µg (P < 0.05).ConclusionBased on the results of the present study, it can be concluded that somatic antigens of protoscolex hydatid cyst are dose‐dependent and antigens with a dose of 20 µg by subcutaneous injection accelerate wound healing and epithelialization.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effect of hydatid cyst protoscolex somatic antigens on full‐thickness skin wound healing in mouse

Hosseinzade,

Nourani,

Kazemi Mehrjerdi

et al. 2024

Skin Research and Technology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nanovaccines also can deal with cancer treatment (Bragazzi, 2019; Ni et al., 2020). Tumour immunotherapy is a new medicinal way to inhibit tumour metastasis and recognize and kill cancer cells, by stimulating the patient's immune responses ( Asouli et al., 2023; Kheirollahpour et al., 2020; Prajapati et al., 2022). Within the field of immuno‐oncology, various modalities have emerged as promising approaches to enhance anti‐tumour immune responses.…”

Section: Introductionmentioning

confidence: 99%

Current status of nano‐vaccinology in veterinary medicine science

Sadr,

Poorjafari Jafroodi,

Haratizadeh

et al. 2023

Veterinary Medicine & Sci

Self Cite

View full text Add to dashboard Cite

Vaccination programmes provide a safe, effective and cost‐efficient strategy for maintaining population health. In veterinary medicine, vaccination not only reduces disease within animal populations but also serves to enhance public health by targeting zoonoses. Nevertheless, for many pathogens, an effective vaccine remains elusive. Recently, nanovaccines have proved to be successful for various infectious and non‐infectious diseases of animals. These novel technologies, such as virus‐like particles, self‐assembling proteins, polymeric nanoparticles, liposomes and virosomes, offer great potential for solving many of the vaccine production challenges. Their benefits include low immunotoxicity, antigen stability, enhanced immunogenicity, flexibility sustained release and the ability to evoke both humoral and cellular immune responses. Nanovaccines are more efficient than traditional vaccines due to ease of control and plasticity in their physio‐chemical properties. They use a highly targeted immunological approach which can provide strong and long‐lasting immunity. This article reviews the currently available nanovaccine technology and considers its utility for both infectious diseases and non‐infectious diseases such as auto‐immunity and cancer. Future research opportunities and application challenges from bench to clinical usage are also discussed.

show abstract

“…Employing pathogenic microorganisms in cancer immunotherapy is not new. Serratia spp, 13 Streptococcus spp, 14 Listeria monocytogenes , 15 Escherichia coli , 16 Lactobacillus casei , 17 Oncolytic virus , 18 Talimogene laherparepve , 19 Newcastle disease virus, 20 yellow fever vaccine 17D, 21 Trypanosoma cruzi , 22 Echinococcus granulosus , 23,24 and Trichinella spiralis , 25 have been shown to eradicate tumor cells 26 . Toxoplasma gondii ( T. gondii ) can regulate innate immune cells by invading myeloid cells, typically producing powerful Th1 immune responses 27 .…”

Section: Introductionmentioning

confidence: 99%

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Lotfalizadeh,

Sadr,

Morovati

et al. 2023

Cancer Reports

Self Cite

View full text Add to dashboard Cite

BackgroundRecently, immunotherapy has become very hopeful for cancer therapy. Cancer treatment through immunotherapy has excellent specificity and less toxicity than conventional chemoradiotherapy. Pathogens have been used in cancer immunotherapy for a long time. The current study aims to evaluate the possibility of Toxoplasma gondii (T. gondii) as a probable treatment for cancers such as melanoma, breast, ovarian, lung, and pancreatic cancer.Recent findingsNonreplicating type I uracil auxotrophic mutants of T. gondii can stimulate immune responses against tumors by reverse immunosuppression at the cellular level. T. gondii can be utilized to research T helper 1 (Th1) cell immunity in intracellular infections. Avirulent T. gondii uracil auxotroph vaccine can change the tumor's immunosuppression and improve the production of type 1 helper cell cytokines, i.e., Interferon‐gamma (IFN‐γ) and Interleukin‐12 (IL‐12) and activate tumor‐related Cluster of Differentiation 8 (CD8+) T cells to identify and destroy cancer cells. The T. gondii profilin protein, along with T. gondii secreted proteins, have been found to exhibit promising properties in the treatment of various cancers. These proteins are being studied for their potential to inhibit tumor growth and enhance the effectiveness of cancer therapies. Their unique mechanisms of action make them valuable candidates for targeted interventions in ovarian cancer, breast cancer, pancreatic cancer, melanoma, and lung cancer treatments.ConclusionIn summary, the study underscores the significant potential of harnessing T. gondii, including its diverse array of proteins and antigens, particularly in its avirulent form, as a groundbreaking approach in cancer immunotherapy.

show abstract

Anti-Tumor Effect of Marshallagia marshalli Somatic Antigen on Inhibition Cell Growth of K562

Cited by 7 publications

References 40 publications

The effect of hydatid cyst protoscolex somatic antigens on full‐thickness skin wound healing in mouse

The effect of hydatid cyst protoscolex somatic antigens on full‐thickness skin wound healing in mouse

Current status of nano‐vaccinology in veterinary medicine science

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Contact Info

Product

Resources

About